Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$24.66 USD
-1.04 (-4.05%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $24.66 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PTGX 24.66 -1.04(-4.05%)
Will PTGX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks to Buy for Attractive Earnings Acceleration
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Other News for PTGX
Protagonist Therapeutics Inc CEO Sells 25,000 Shares
Protagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic Partnerships
Protagonist expects to reach VERIFY enrollment target by end of March
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Catalyst Watch: Walgreens earnings, UPS analyst day and Xiaomi's luxury EV debut